ProMIS Neurosciences grants CSO 50,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ProMIS Neurosciences Inc. reported that Chief Scientific Officer Neil Cashman received a grant of options to buy 50,000 Common Shares. These options have an exercise price of $10.77 per share and expire on May 20, 2036. The award was made at no cost to him and represents equity-based compensation rather than an open-market purchase or sale. According to a footnote, the options vest ratably over four years, contingent on his continued service with the company. Following this grant, he holds 50,000 options directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 50,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.
Key Figures
Key Terms
Option (right to buy) financial
Grant, award, or other acquisition financial
vest ratably over four years financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ProMIS Neurosciences (PMN) report for Neil Cashman?
What is the exercise price of Neil Cashman’s new ProMIS Neurosciences options?
When do Neil Cashman’s ProMIS Neurosciences options expire?
How do Neil Cashman’s ProMIS Neurosciences options vest over time?
AI-generated analysis. How Rhea-AI works. Not financial advice.